Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTEMS trial of GT-002 acute psychophysiological effects in schizophrenia spectrum disorders
2024-519389-28-00Phase 2Authorised
- Sponsor
- Region Hovedstadens Psykiatri
- Start
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of peptide YY 3-36 in Schizophrenia Spectrum Disorders (SSD) and schizophrenia (6 arms), sponsored by Region Hovedstadens Psykiatri. Primary endpoint: Pre-pulse Inhibition of the Startle Reflex. Planned start May 2026; status: authorised.
02
Drugs
peptide YY 3-36
03
Conditions
Schizophrenia Spectrum Disorders (SSD)schizophrenia
Beyond the preview
Go deeper on 2024-519389-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519389-28-00.